Application of flavonoid compound in preparation of medicine for preventing and treating abdominal aortic aneurysm

By using flavonoid HSYA to inhibit inflammatory infiltration of abdominal aortic aneurysm and apoptosis of smooth muscle cells, the problem of insufficient AAA treatment in the prior art is solved, and new drug development strategies for preventing and treating AAA are provided, and AAA pathology is achieved. Improvement of injury.

CN118892479APending Publication Date: 2024-11-05HENAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411083200.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-05

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention discloses application of a flavonoid compound in preparation of a medicine for preventing and treating abdominal aortic aneurysm. The flavonoid compound is hydroxysafflor yellow A (HSYA). The invention proposes that the hydroxysafflor yellow A can improve the abdominal aortic aneurysm AAA by inhibiting aortic adventitia inflammation infiltration, matrix metalloproteinase expression and the like for the first time, reveals the new application of the HSYA, and provides a new thought for preventing and treating the abdominal aortic aneurysm.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and specifically relates to application of a flavonoid compound in preparing a medicine for preventing and treating abdominal aortic aneurysm. Background Art

[0002] Abdominal aortic aneurysm (AAA) is a cardiovascular disease (CVD). Clinically, AAA usually remains silent unless the AAA increases in size rapidly, ruptures acutely, or embolizes to distal arteries. When the intraluminal pressure and wall stress exceed the strength of the aortic wall, the aorta will rupture, which can lead to serious consequences with a mortality rate of up to 80%. The main pathology of AAA is a dynamic and complex process that ultimately leads to irreversible damage to the extracellular matrix. In the past few decades, a large number of natural products have been studied for their effects on cardiovascular diseases. How to find effective drugs to inhibit AAA development and rupture is of great clinical significance.

[0003] Safflower is a plant used for both medicine and food, and hydroxysafflor yellow A (HSYA) is one of the main active chalcone glycosides in safflower. However, there are no reports on the effect of HSYA on abdominal aortic aneurysm (AAA).

[0004] Based on this, this application was developed. Summary of the invention

[0005] The purpose of the present invention is to overcome the defects of the prior art and provide an application of a flavonoid compound in the preparation of a drug for preventing and treating abdominal aortic aneurysm. In vivo and in vitro experiments show that the flavonoid compound HSYA has a certain preventive and therapeutic effect on abdominal aortic aneurysm (AAA), and can be used as a drug for the preparation of a drug for preventing and treating abdominal aortic aneurysm, solving the problem that there is no hydroxysafflor yellow A (HSYA) in the prior art for treating AAA.

[0006] To achieve the above object, the present invention adopts the following technical solution: A flavonoid compound is used in the preparation of a drug for preventing and treating abdominal aortic aneurysm, wherein the flavonoid compound is hydroxysafflor yellow A (HSYA). That is, the present invention discloses the role of a flavonoid compound hydroxysafflor yellow A (HSYA) in preventing and treating abdominal aortic aneurysm, reveals a new use of HSYA, and provides a new idea for preventing and treating abdominal aortic aneurysm.

[0007] Specifically, in the above application, the flavonoid compound can improve the pathological damage of abdominal aortic aneurysm.

[0008] Furthermore, in the above application, the flavonoid compound can inhibit adventitial inflammatory infiltration and inhibit smooth muscle cell apoptosis.

[0009] The present invention provides a drug for preventing and treating abdominal aortic aneurysm, which comprises the flavonoid compound hydroxysafflor yellow A (HSYA). The drug for preventing and treating abdominal aortic aneurysm can be prepared into tablets, granules, pills, capsules or injections by selecting conventional pharmaceutical excipients in the art.

[0010] The invention provides a research method for preventing and treating abdominal aortic aneurysm using flavonoid compounds, which comprises the following steps.

[0011] Step 1: Use calcium chloride and elastase to establish mouse model; Step 2: While the mice were modeling, HSYA was administered through the tail vein; Step 3: Evaluate the improvement of AAA pathology by HE / EVG / MASSON staining; Step 4: Isolate the abdominal aorta of mice and explore its mechanism by RT-QPCR and Western Blot methods; Step 5: Finally, the effect of HSYA on mouse vascular smooth muscle cells (MOVAS) was evaluated.

[0012] Specifically, in step 1, there are two mouse modeling methods: one is to apply 2U elastase to the abdominal aorta for 30 minutes; the other is to apply 0.75 mol / L CaCl 2 The aorta was incubated for 20 min and then replaced with PBS for 10 min.

[0013] Furthermore, in step 1, the PPE model was administered with HSYA at a dose of 18, 9, or 4.5 mg / kg / d in the tail vein for two weeks; CaCl 2 The model was given once every two days at a dose of 18 mg / kg / d.

[0014] Specifically, the concentration used in step 5 is 1×10 -4 mol / L Ang II was used to model MOVAS cells, and the concentrations of HSYA were 100, 50, and 25 μmol / L.

[0015] Compared with the prior art, the advantages and beneficial effects of the present invention are as follows: The present invention proposes for the first time that HSYA can improve the pathological symptoms of abdominal aortic aneurysm, which may be achieved by inhibiting adventitial inflammatory infiltration and smooth muscle cell apoptosis. The present invention evaluates the effects of HSYA in multiple in vivo models and in vitro, which helps to reveal the new effects of the clinical drug hydroxysafflor yellow A and provides new ideas and drug development strategies for the prevention and treatment of abdominal aortic aneurysm. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1The effect of hydroxysafflor yellow A on abdominal aortic aneurysm in elastase-induced mice is shown in Figure 1, where A: drug administration flow chart, B: abdominal aorta sampling diagram of mice, C: maximum diameter quantitative diagram of abdominal aorta of mice, D: PCR detection of IL-1β, MCP-1, MMP-2, MMP-9 and other related factors, E: HE staining of abdominal aorta of mice, F: EVG staining of abdominal aorta of mice, G: Masson staining of abdominal aorta of mice, and H: quantitative diagram of Masson staining positive area; Figure 2 The effect of hydroxysafflor yellow A on abdominal aortic aneurysm in calcium chloride-induced mice, where A: drug administration flow chart, B: abdominal aorta sampling diagram of mice, C: maximum diameter quantitative diagram of abdominal aorta of mice, D: PCR detection of MMP-2, BCL-2, TNF-α, IL-6 and other related factors, E: HE and EVG staining of abdominal aorta of mice, F: Masson staining of abdominal aorta of mice, G: Masson staining positive area quantitative diagram; Figure 3 The diagram shows the effect of hydroxysafflor yellow A on mouse vascular smooth muscle cells. A: MTT method was used to detect the cytotoxicity of hydroxysafflor yellow A. B: PCR method was used to detect related factors such as MMP-2, MMP-9, and IL-6. C: WB method was used to detect the expression of related proteins such as NOX2, Caspase3, Caspase9, MMP-2, and MMP-9. DETAILED DESCRIPTION

[0017] The technical solution of the present invention is further described in detail below in conjunction with the embodiments. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments, and the protection scope of the present invention is not limited thereto.

[0018] The innovation and core of the present invention lies in the discovery of a new use of the flavonoid compound hydroxysafflor yellow A (HSYA) in the preparation of drugs for the prevention and treatment of abdominal aortic aneurysms, providing a new idea for the prevention and treatment of abdominal aortic aneurysms. The operations involved or used in the mouse experiments in the embodiments, unless otherwise described in detail, can be carried out using conventional techniques in the art.

[0019] Example 1 The invention discloses an application of a flavonoid compound in preparing a drug for preventing and treating abdominal aortic aneurysm. The flavonoid compound is hydroxysafflor yellow A (HSYA).

[0020] This embodiment provides a research method for the prevention and treatment of abdominal aortic aneurysm using flavonoid compounds (hydroxysafflor yellow A, HSYA), which specifically includes the following steps: Step 1: Use calcium chloride and elastase to establish mouse model; Step 2: While the mouse model was being established, HSYA was administered through the tail vein; Step 3: Evaluate the improvement of AAA pathology by HE / EVG / MASSON staining; Step 4: Isolate the abdominal aorta of mice and explore its mechanism by RT-QPCR and Western Blot methods; Step 5: Finally, evaluate the effect of HSYA in vitro.

[0021] In this case, it was proposed for the first time that HSYA can improve the symptoms of abdominal aortic aneurysm, possibly by inhibiting adventitial inflammatory infiltration and smooth muscle cell apoptosis. The effects of HSYA were evaluated in multiple in vivo models and in vitro, which helped to reveal new effects of the clinical drug hydroxysafflor yellow A and provided new ideas and drug development strategies for the prevention and treatment of abdominal aortic aneurysm.

[0022] Example 2 The mice used in this example were C57BL / 6J mice purchased from Henan Sikebes Biotechnology Co., Ltd. All animal operations involved in the experiment were in compliance with ethical requirements.

[0023] 1 Experimental animals Healthy C57BL / 6 mice, SPF grade, 6-8 weeks old, weighing 20-22 g, were purchased from Henan Sikebes Biotechnology Co., Ltd. The experimental animal license number is SCXK (Yu) 2020-005.

[0024] 2 Experimental Materials Calcium chloride (Aladdin); Elastase (PPE, Sigma); Hydroxysafflor yellow A (Chengdu Pufeide Biotechnology Co., Ltd.); RNA extraction solution (Wuhan Saiweier Biotechnology Co., Ltd.); Fluorescence inverted microscope (Nikon); Electronic balance (Mettler-Toledo, USA); Refrigerated centrifuge (Thermo); Mouse anesthesia apparatus (SIFARY); Isoflurane (Vorade); RIPA lysis buffer (Biyuntian).

[0025] 3 In vivo experimental methods 3.1 PPE-induced abdominal aortic aneurysm model in mice Mice were anesthetized by inhalation of 4% isoflurane and continuous anesthesia with 2% isoflurane. The mice were positioned in the supine position, shaved and disinfected. A midline incision of the abdomen was made, about 1.5 cm long. The skin and muscles were cut layer by layer to enter the abdominal cavity. The intestinal tube was pushed out of the abdominal cavity to fully expose and free the abdominal aorta segment below the level of the renal artery and above the level of the iliac artery. The tissues around the abdominal aorta were separated and protected with cotton balls. The mice were wrapped with a 1 cm wide cotton pad on the surface of the abdominal aorta. The mixed elastase (2U) was evenly injected on the cotton pad with a pipette. The mixture was incubated for 30 min. The residual solution was absorbed by a dry cotton ball, and the solution was rinsed with saline. The abdomen and skin were sutured with wound clips.

[0026] 3.2 Administration The mice were divided into sham group (Sham), PPE (2U) group, and HSYA group (18, 9, 4.5 mg / kg / d). The abdominal aorta was freed in the sham group without medication, and cotton containing 2U elastase was incubated on the abdominal aorta in the PPE group. The medication group started medication on the second day after the model was established, and the medication lasted for 2 weeks. After two weeks, the aorta was dissected and obtained for the next experiment.

[0027] 3.3 Morphological observation Mice were anesthetized by inhalation of 4% isoflurane, and the chest muscles, sternum, and pericardium were cut in sequence to expose the heart. The apex of the heart was punctured, the right atrial appendage was cut, and saline was perfused along the left ventricle. At the same time, the abdominal skin, muscles, and peritoneum were cut. After the liver turned white, it was replaced with 0.9% saline precooled at 4°C for rapid perfusion and then the aortic tissue was obtained. The diameter of the infiltrated abdominal aorta was measured with a vernier caliper before sampling, and the abdominal aortic expansion rate was calculated.

[0028] 3.4 RT-QPCR detection of related factors After the mice were killed, the infrarenal segment of the abdominal aorta was isolated for testing. 1 ml of RNA extraction solution (G3013-100ML, Wuhan Sevier) was added, and the aorta was homogenized to extract aortic RNA. The gDNA was removed using the SweScript All-in-One RT SuperMixfor qPCR kit and reverse transcription was performed. Finally, 2×Universal Blue SYBR Green reagent (Sevier, G3326) was used to amplify IL-1β, MCP-1, MMP-2, and MMP-9 (the amplification process was carried out according to the reagent instructions and will not be repeated here). After the amplification, according to 2 -△△Ct The relative expression was calculated by the β-actin method, and β-actin was used as the internal reference.

[0029] 3.5 HE staining After the mouse aorta was collected, it was immediately fixed in tissue fixative for more than 24 hours, dehydrated, paraffin-immersed, paraffin-embedded, and paraffin-sectioned, and then the sections were stained with hematoxylin-eosin.

[0030] 3.6 EVG staining After the mouse aorta was collected, it was immediately fixed in 4% paraformaldehyde (tissue fixative) for more than 24 hours, dehydrated, paraffin-immersed, paraffin-embedded, and paraffin-sectioned. The sections were then stained with an EVG staining kit and finally counterstained with EVG.

[0031] 3.7 Masson staining After the mouse aorta was collected, it was immediately fixed in tissue fixative for more than 24 hours, dehydrated, paraffin-immersed, paraffin-embedded, and paraffin-sectioned, and then the sections were stained using a Masson staining kit.

[0032] In this example. Figure 1 As shown in B, after incubation with PPE, significant dilation of the aorta was observed. After administration of HSYA, the three dose groups all had varying degrees of inhibitory effects and were able to slow down the development of abdominal aortic aneurysm. Figure 1 C The maximum diameter of the abdominal aorta in each group was quantified. The results showed that HSYA could slow down the expansion of the aorta. Figure 1 B is consistent. Figure 1 D is the result of detecting related factors by RT-QPCR method, and the figure shows that HSYA can inhibit the increase of IL-1β, MCP-1, MMP-2, and MMP-9 caused by AAA. Figure 1 E The pathological condition was detected by HE staining, and the figure shows that the administration of HSYA can improve the outer membrane inflammatory cell infiltration and middle membrane rupture caused by AAA. Figure 1 F Through EVG staining, compared with the AAA group, the HSYA-treated group could improve the elastic fiber degradation and disorder caused by AAA. Figure 1 G Masson staining showed: elastin degradation and abnormal collagen accumulation, which could be reversed after HSYA administration. Figure 1 H quantified the area of ​​Masson-stained positive collagen fibers, and the figure shows that administration of the drug can alleviate the abnormal accumulation of collagen fibers caused by abdominal aortic aneurysm.

[0033] These results indicate that HSYA may slow down the development of AAA by reducing inflammatory infiltration and inhibiting elastin degradation.

[0034] Example 3 The mice used in the examples were C57BL / 6J mice purchased from Henan Sikebes Biotechnology Co., Ltd. All animal operations involved in the experiments were in compliance with ethical requirements.

[0035] 3 In vivo experimental methods 3.1 CaCl 2 Model of abdominal aortic aneurysm in mice Mice were anesthetized by inhalation of 4% isoflurane, positioned supine, shaved, and disinfected. A midline incision of about 1.5 cm was made in the abdomen, and the skin and muscles were cut layer by layer to enter the abdominal cavity. The intestinal tract was pushed out of the abdominal cavity, and the abdominal aorta segment of about 0.5 cm below the level of the renal artery and above the level of the iliac artery was fully exposed and freed. The tissues around the abdominal aorta were separated and protected with cotton balls. Mice were irrigated with 0.75 mol / L CaCl 2 The cotton ball with the solution was soaked on the surface of the abdominal aorta for 20 min, and the PBS solution was applied to the abdominal aorta for 10 min. The residual CaCl was absorbed by the dry cotton ball. 2 The solution was washed with saline and the abdomen and skin were sutured with wound clips.

[0036] 3.2 Administration The mice were divided into sham group (Sham), 0.75 mol / L CaCl 2 The abdominal aorta was freed and no drug was given. 0.75 mol / L CaCl 2 The abdominal aorta of the group was incubated with 0.75 mol / L CaCl 2 The drug-treated group began to be injected into the tail vein on the second day after the model was established, and the drug was administered once every two days for 4 weeks. After four weeks, the aorta was dissected and obtained for the next experiment.

[0037] 3.3 Morphological observation Mice were anesthetized by inhalation of 4% isoflurane, and the chest muscles, sternum, and pericardium were cut in turn to expose the heart. The apex of the heart was punctured, the right atrial appendage was cut, and saline was perfused along the left ventricle. At the same time, the abdominal skin, muscles, and peritoneum were cut. After the liver turned white, it was replaced with pre-cooled 0.9% saline for rapid perfusion and then the aortic tissue was obtained. The diameter of the infiltrated abdominal aorta was measured with a vernier caliper before sampling, and the abdominal aortic expansion rate was calculated.

[0038] 3.4 RT-QPCR detection of related factors After the mice were killed, the infrarenal segment of the abdominal aorta was isolated for testing. 1 ml of RNA extraction solution was added, and the aorta was homogenized to extract aortic RNA. The gDNA was removed using the SweScript All-in-One RT SuperMix for qPCR kit and reverse transcribed. Finally, 2×Universal Blue SYBR Green reagent was used to amplify MMP-2, BCL-2, TNF-α, and IL-6. After amplification, the RNA was analyzed according to the 2-△△CtThe relative expression was calculated by the β-actin method, and β-actin was used as the internal reference.

[0039] 3.5 HE staining After the mouse aorta was collected, it was immediately placed in tissue fixative for more than 24 hours, dehydrated, wax-immersed, paraffin-embedded, and paraffin-sectioned, and then the sections were stained with hematoxylin-eosin.

[0040] 3.6 EVG staining After the mouse aorta was collected, it was immediately fixed in 4% paraformaldehyde (tissue fixative) for more than 24 hours, dehydrated, paraffin-immersed, paraffin-embedded, and paraffin-sectioned. The sections were then stained with an EVG staining kit and finally counterstained with EVG.

[0041] 3.7 Masson staining After the mouse aorta was collected, it was immediately fixed in tissue fixative for more than 24 hours, dehydrated, paraffin-immersed, paraffin-embedded, and paraffin-sectioned, and then the sections were stained using a Masson staining kit.

[0042] In this example. Figure 2 As shown in B, CaCl 2 After incubation, obvious dilation of the aorta was observed. After administration of HSYA, the drug-treated groups all had varying degrees of inhibitory effects, which could slow down the development of abdominal aortic aneurysm. Figure 2 C The maximum diameter of the abdominal aorta in each group was quantified, and the results showed that HSYA could slow down the dilatation of the aorta. Figure 2 D. RT-QPCR method was used to detect related factors. The results in the figure show that HSYA can inhibit the increase of IL-6, TNF-α, MMP-2 and the decrease of BCL-2 caused by AAA. Figure 2 E The pathological condition was detected by HE staining. The HE staining results in the figure showed that HSYA could improve the outer membrane inflammatory cell infiltration and middle membrane rupture caused by AAA. EVG staining results showed that compared with the AAA group, HSYA could improve the elastic fiber degradation and disorder caused by AAA. Figure 2 F shows the degradation of elastin and abnormal accumulation of collagen by Masson staining, which can be reversed after drug administration. Figure 2 G was used to quantify the area of ​​Masson-stained positive collagen fibers. The results showed that administration of the drug could alleviate the abnormal accumulation of collagen fibers caused by abdominal aortic aneurysm.

[0043] The above results indicate that HSYA may improve the characteristics of AAA by inhibiting the apoptosis of smooth muscle cells, elastin degradation, and infiltration of inflammatory cells.

[0044] Example 4 4.1 Cell culture Mouse aortic smooth muscle cells (MOVAS) were purchased from ATCC (CRL-2797) and placed in DMEM medium containing 10% fetal bovine serum, 0.2 mg / mL geneticin (G-418), 100 U / mL penicillin, and 100 g / mL streptomycin at 37°C in an atmosphere of 95% air and 5% CO. 2 When the cell density reached 80%, the culture medium was changed to DMEM medium without fetal bovine serum for 24 h to synchronize the cell growth cycle. The cells at this time were used for the following experiments.

[0045] 4.2 Cell viability test Mouse aortic smooth muscle cells (MOVAS) were inoculated into a sterile 96-well cell culture plate. Six replicate wells were set up in each group. 100 μL of cell suspension was added to each well and the plate was incubated at 37°C and 5% CO. 2 After culturing for 24 h, the cells were pretreated with different concentrations of HSYA (200, 100, 50, 25, 12.5, and 6.25 μmol / L) for 24 h, and 500 μL of AngII (1×10 -4 After culturing for 24 h, 10 μL of MTT (tetrazolium salt) reagent was added and incubated for another 4 h at 37 °C. The absorbance (OD) value was measured at 490 nm using an enzyme reader and compared with the absorbance value of the blank group.

[0046] 4.3 RT-QPCR to determine the expression levels of cell-related factors MOVAS cells were inoculated in 24-well plates, and blank group, model group, and HSYA-treated group (100, 50, and 25 μmol / L) were set up. Two replicate wells were set up in each group and the plates were incubated at 37°C and 5% CO. 2 After culturing for 24 h, the original culture medium was discarded and 500 μL of AngII (1×10 -4 mol / L) solution. After culturing for 24 hours, the cells were collected. 1 ml of RNA extraction solution was added, and gDNA was removed using the SweScript All-in-One RT SuperMix for qPCR kit for reverse transcription. Finally, 2×Universal BlueSYBR Green reagent was used to amplify MMP-2, MMP-9, and IL-6. After amplification, 2-△△Ct The relative expression was calculated by the β-actin method, and β-actin was used as the internal reference.

[0047] 4.4 Western Blot method to determine the expression level of cell-related proteins (1) MOVAS cells were inoculated in 6-well plates and the blank group, model group, and HSYA-treated group (100, 50, and 25 μmol / L) were set up at 37°C and 5% CO. 2 After culturing for 24 h, the original culture medium was discarded and 500 μL of AngII (1×10 -4 After culturing for 24 hours, the cells were collected and 100 μL of RIPA lysis buffer (P0013B, Bio-Tech) was added. The cells were lysed on ice for 30 minutes and centrifuged at 4°C, 12,000 r / min for 10 minutes. The supernatant was the protein solution. The protein was extracted for concentration determination.

[0048] (2) Protein concentration determination: Take 2 µL of protein solution, dilute it 10 times with PBS, then add 200 µL of BCA working solution (Solabo, PC0020), shake, incubate at 37°C for 30 min, measure the absorbance at 562 nm, substitute it into the standard curve, and calculate the protein concentration and sample volume.

[0049] (3) Separation of target protein: ① Deionized water: 1.9 mL, 30% acrylamide: 1.7 mL, 1.5 mol / L Tris-HCl: 0.05 mL, 10% SDS: 0.05 mL, 10% ammonium persulfate: 0.05 mL, TEMED: 0.002 mL were used to prepare SDS polyacrylamide gel, and 1× protein electrophoresis buffer was added for electrophoresis. Conditions: 80 V, 30 min, the protein samples were compressed on a uniform horizontal line, and then 120 V, 60 min for protein separation.

[0050] ② Transfer: After electrophoresis, use the "sandwich method" to transfer the membrane, add 1× transfer solution to the electrophoresis tank, voltage 72 V, time 60 min.

[0051] ③ Blocking: Block in 5% skimmed milk powder for 2 h.

[0052] ④ Incubate with primary antibody: According to the Marker indication, determine the location of proteins such as β-ATTIN, NOX2, Casepase-3, Caspase-9, MMP-2, MMP-9, etc. and cut them, then incubate the bands with the corresponding primary antibodies at 4°C overnight.

[0053] ⑤ Washing the membrane: After incubation with the primary antibody, wash the protein bands in TBST solution 5 times, 5 min each time.

[0054] ⑥ Incubate with secondary antibody: According to the source of primary antibody, add corresponding secondary antibody at room temperature for 1~2 h.

[0055] ⑦ Wash the membrane: Wash the protein bands 5 times in the same TBST solution, 5 min each time.

[0056] ⑧ Development analysis: Evenly apply the developer and then develop the image, using β-actin as an internal reference.

[0057] In this example. Figure 3 As shown in A, HSYA was toxic to cells at 200 μmol / L, but had no toxicity to MOVAS cells at 6.25-100 μmol / L. Figure 3 B shows that after administration of HSYA, the expression levels of factors such as MMP-2, MMP-9, and IL-6 can be inhibited. Figure 3 C shows that through Western Blot experiments, it was found that HSYA had a significant improvement effect on proteins such as NOX2, MMP-2, MMP-9, Casepase-3, and Caspase-9.

[0058] In conclusion, HSYA may slow down the development of AAA by reducing adventitial inflammatory infiltration, inhibiting smooth muscle cell apoptosis and elastin degradation.

Claims

1. A use of a flavonoid compound in the preparation of a drug for preventing and treating abdominal aortic aneurysm, characterized in that: The flavonoid compound is hydroxysafflor yellow A.

2. The use of the flavonoid compound according to claim 1 in the preparation of a drug for preventing and treating abdominal aortic aneurysm, characterized in that: The flavonoid compound can improve the pathological damage of abdominal aortic aneurysm.

3. The use of the flavonoid compound according to claim 2 in the preparation of a drug for preventing and treating abdominal aortic aneurysm, characterized in that: The flavonoid compound can inhibit adventitial inflammatory infiltration and inhibit smooth muscle cell apoptosis.

4. A drug for preventing and treating abdominal aortic aneurysm, characterized in that: Contains the flavonoid compound according to claim 1.

5. The drug for preventing and treating abdominal aortic aneurysm according to claim 4, characterized in that: The conventional pharmaceutical excipients in the art are selected to prepare tablets, granules, pills, capsules or injections.